Publications
DrugCentral is a drug information resource (http://drugcentral.org) open to the public since 2016 and previously described in the 2017 Nucleic Acids Research Database issue. Since the 2016 release, 103 new approved drugs were updated. The following new data sources have been included: Read more “DrugCentral 2018: An Update in Nucleic Acids Research”
Publications
Resveratrol (3, 4′, 5-trihydroxy-trans-stilbene) is a natural phytoalexin found in grapes and has long been thought to be the answer to the “French Paradox.” There is no shortage of preclinical and clinical studies investigating the broad therapeutic activity of resveratrol. However, in spite of many comprehensive reviews published on the bioactivity of resveratrol, Read more “Structural Interactions of Resveratrol With Its Bandwagon of Targets”
Publications
The NIH-funded LINCS Consortium is creating an extensive reference library of cell-based perturbation response signatures and sophisticated informatics tools incorporating a large number of perturbagens, model systems, and assays. To date, more than 350 datasets have been generated including transcriptomics, proteomics, epigenomics, cell phenotype and competitive binding profiling assays. Read more “Sustainable Data and Metadata Management at the BD2K-LINCS DCIC”
Publications
Chromatin-modifying enzymes, and specifically the protein arginine methyltransferases (PRMTs), have emerged as important targets in cancer. Here, we investigated the role of CARM1 in normal and malignant hematopoiesis. Read more “CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis”
Publications
A large proportion of biomedical research and the development of therapeutics is focused on a small fraction of the human genome. In a strategic effort to map the knowledge gaps around proteins encoded by the human genome and to promote the exploration of currently understudied, but potentially druggable, proteins, the US National Institutes of Health launched the Illuminating the Druggable Genome (IDG) initiative in 2014. Read more “Unexplored Therapeutic Opportunities in the Human Genome”
Publications
There is an expectation that scientists will archive their experimental data online in public repositories to enable other investigators to verify their work and to re-explore their data in search of new discoveries. When left to their own devices, however, scientists do a poor job creating the metadata that describe their datasets. Read more “CEDAR: Semantic Web Technology to Support Open Science”
Publications
Glioblastoma multiforme (GBM) is the most malignant primary adult brain tumor. The current standard of care is surgical resection, radiation, and chemotherapy treatment, which extends life in most cases. Unfortunately, tumor recurrence is nearly universal and patients with recurrent glioblastoma typically survive less than one year. Read more “Drug Repositioning in Glioblastoma: A Pathway Perspective”
News - Archived
Ontology sounds a lot like a medical specialty—but it’s not related to Oncology, Otolaryngology, or Ophthalmology—except that researchers organizing Big Data in Biomedicine into different ‘ontologies’ or categories could help expedite new drug targets and discoveries in these specialties, and others, in the future.
The University of Miami Miller School of Medicine is joining a partnership to combine advances in ontologies, templates, and other research tools to take digital biomedical research data to the next level. Read more “Public-Private Partnership to Facilitate Ontology Use and Application”
News
If you build it, the data will not only come, it will be standardized, accessible, and reusable by researchers around the world. With this in mind, the National Institutes of Health (NIH) is creating its Data Commons initiative, and recently invited University of Miami investigators to contribute their expertise. “There is a big effort at the NIH now to bring biomedical research into the data science era. Data science including machine learning is all around us—like recommendation engines for shopping or movies, image and voice recognition, language translation, even the news you see on social media, and your personalized internet search results,” said Stephan Schürer, PhD, Program Director, Drug Discovery, and Associate Professor of Molecular and Cellular Pharmacology at the University of Miami Miller School of Medicine. Read more “IDSC joins International NIH Data Commons Consortium”
News
It’s part genomics*, part big data, and all about driving discoveries that could someday translate to new treatments for cancer, neurological diseases, addiction, and many other conditions, said Stephan Schürer, Ph.D., CCS Drug Discovery program director, and associate professor of molecular and cellular pharmacology at the UM Miller School of Medicine.
The NIH’s “Illuminating the Druggable Genome“ (IDG) initiative is expected to generate a lot of scientific information from several investigators at leading institutions nationwide. Schürer has been appointed to the IDG’s Resource Dissemination and Outreach Center to organize the incoming data and coordinate project resources. Read more “Genomics meets Big Data in Illuminating the Druggable Genome”